

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/237159 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) C07K 14/435 (2006.01)
A61K 39/395 (2006.01) C07K 16/46 (2006.01)
C07K 14/00 (2006.01) C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2021/033759

(22) International Filing Date:

21 May 2021 (21.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/029,062 22 May 2020 (22.05.2020) US

(71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney Avenue, New Haven, Connecticut 06510 (US).

(72) Inventors: SIMONS, Michael; 81 Church Street, Unit 5E, New Haven, Connecticut 06510 (US). CORTI, Federi-

co; 265 College Street, Unit 5C, New Haven, Connecticut 06510 (US).

(74) Agent: DOYLE, Kathryn et al.; Saul Ewing Arnstein & Lehr LLP, 1500 Market Street, 38th Floor, Centre Square West, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: METHODS AND COMPOSITIONS TO TREAT VASCULAR LEAK




FIG. 1A

(57) Abstract: Provided are anti-syndecan-2 antibodies and compositions comprising said antibody and methods useful for treating acute respiratory distress syndrome, including coronavirus disease 2019-induced acute respiratory distress syndrome, in a subject in need thereof. The method comprises administering to the subject an effective amount to treat the acute respiratory distress syndrome of an syndecan-2 disrupting agent. The syndecan-2 disrupting agents may include at least one of the anti-syndecan-2 antibodies and/or at least one syndecan-2 disrupting peptide.

[Continued on next page]

WO 2021/237159 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*